Viracept Expanded Access Program
|ClinicalTrials.gov Identifier: NCT00002165|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of <= 50. To obtain additional information on the safety profile of nelfinavir mesylate (Viracept).
(PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
|Condition or disease||Intervention/treatment|
|HIV Infections||Drug: Nelfinavir mesylate|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Viracept Expanded Access Program|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002165
|United States, California|
|Agouron Pharmaceuticals Inc|
|San Diego, California, United States, 92121|